Insmed Inc (NASDAQ: INSM)’s stock price has increased by 1.36 compared to its previous closing price of 28.01. However, the company has seen a 2.57% increase in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-02-22 that Insmed (INSM) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.20 per share a year ago.
Is It Worth Investing in Insmed Inc (NASDAQ: INSM) Right Now?
Moreover, the 36-month beta value for INSM is 0.91. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for INSM is 144.65M and currently, short sellers hold a 6.25% of that float. On April 11, 2024, INSM’s average trading volume was 1.64M shares.
INSM’s Market Performance
INSM’s stock has seen a 2.57% increase for the week, with a 4.84% rise in the past month and a -2.47% fall in the past quarter. The volatility ratio for the week is 3.13%, and the volatility levels for the past 30 days are at 3.16% for Insmed Inc The simple moving average for the past 20 days is 5.34% for INSM’s stock, with a 11.45% simple moving average for the past 200 days.
Analysts’ Opinion of INSM
Many brokerage firms have already submitted their reports for INSM stocks, with Wolfe Research repeating the rating for INSM by listing it as a “Outperform.” The predicted price for INSM in the upcoming period, according to Wolfe Research is $42 based on the research report published on February 15, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see INSM reach a price target of $55. The rating they have provided for INSM stocks is “Overweight” according to the report published on December 08th, 2023.
JP Morgan gave a rating of “Overweight” to INSM, setting the target price at $36 in the report published on November 20th of the previous year.
INSM Trading at 2.54% from the 50-Day Moving Average
After a stumble in the market that brought INSM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.28% of loss for the given period.
Volatility was left at 3.16%, however, over the last 30 days, the volatility rate increased by 3.13%, as shares surge +3.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.78% upper at present.
During the last 5 trading sessions, INSM rose by +2.57%, which changed the moving average for the period of 200-days by +42.23% in comparison to the 20-day moving average, which settled at $27.01. In addition, Insmed Inc saw -8.39% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at INSM starting from Adsett Roger, who sale 5,251 shares at the price of $28.63 back on Jan 12 ’24. After this action, Adsett Roger now owns 148,559 shares of Insmed Inc, valued at $150,336 using the latest closing price.
Flammer Martina M.D., the Chief Medical Officer of Insmed Inc, sale 4,667 shares at $28.63 during a trade that took place back on Jan 12 ’24, which means that Flammer Martina M.D. is holding 106,898 shares at $133,616 based on the most recent closing price.
Stock Fundamentals for INSM
Current profitability levels for the company are sitting at:
- -2.36 for the present operating margin
- 0.79 for the gross margin
The net margin for Insmed Inc stands at -2.46. The total capital return value is set at -0.65. Equity return is now at value -1453.41, with -50.20 for asset returns.
Based on Insmed Inc (INSM), the company’s capital structure generated 1.38 points at debt to capital in total, while cash flow to debt ratio is standing at -0.45. The debt to equity ratio resting at -3.63. The interest coverage ratio of the stock is -9.23.
Currently, EBITDA for the company is -673.93 million with net debt to EBITDA at -1.09. When we switch over and look at the enterprise to sales, we see a ratio of 16.18. The receivables turnover for the company is 7.41for trailing twelve months and the total asset turnover is 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.12.
Conclusion
To wrap up, the performance of Insmed Inc (INSM) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
